1.The clinical value of Thinprep cytology test combined with h -TERC and c -myc in the diagnosis of cervical ;cancer
Chinese Journal of Primary Medicine and Pharmacy 2015;(21):3211-3213
Objective To explore the clinical value of Thinprep cytology test (TCT)combined with h -TERC and c -myc in the diagnosis of cervical cancer.Methods hTERC amplification was detected by dual -color interphase fluorescence in situ hybridization (FISH),and the results were compared with TCT and histological examination.Examination the positive which TCT,h -TERC and c -myc by pathological examination.The final diag-nosis was determined by the pathological examination.Results TCT was abnormal in 26.4% of 500 case,18.0%abnormal h -TERC gene,16.0% abnormal c -myc gene.In 270 cases according to the cervical biopsy,the positive rate of chronic inflammation,cervical intraepithelial neoplasia (CIN)Ⅰ,CINⅡ,CINⅢ and cervical cancer:44.4%, 38.2%,36.4%,18.2%,and 7.3% respectively.The positive rates of h -TERC were 18.1%,45.4%,52.5%, 65.9% and 100.0%,respectively.The positive rates of c -myc were 21.4%,48.9%,56.7%,59.9% and 100.0%.With increased pathological grade,the expressions of h -TERC and c -myc were high.Conclusion TCT combined with h -TERC and c -myc can test cervical cancer more effective.
2.A study on lymph node metastasis in early gastric carcinoma
Yanbing ZHOU ; Hao WANG ; Shikuan LI ; Weizheng MAO ; Haibo WANG
Chinese Journal of General Surgery 2008;23(6):408-410
Objective To study lymph node metastasis in early gastric carcinoma. Methods From July 2001 to July 2007, 177 patients with early gastric carcinoma underwent radical gastrectomy and the clinicopathologic data were analyzed by binary logistic regression. Results The overall rate of lymph node metastasis in early gastric carcinoma was 13%, involving 13% and 3% in level I (NI) and level Ⅱlymph nodes (N2), respectively. The rate of lymph node metastasis was 22%(20/89) in cases of submucosal lesion (SM), which was significantly higher than 3%(3/88) in cases of mucosal lesion (M) (X2=14. 222, P<0.01). The rate of lymph node metastasis was 3%(4/117) when the primary tumor was ≤2cmin diameter compared with 32%(19/60) when the tumor was >2cm (X2=27.992, P<0.01). The lymph node metastasis rate was 4%(3/81) and 21%(20/96) in differentiated and undifferentiated lesion (X2=11.402, P=0.001), and it was 33%(2/6)、8%(7/99) and 19% (14/92) in macroscopic type I, Ⅱ and Ⅲ (X2=8.172, P=0.014). Binarylogistic analysis found that the tumour diameter greater than 2.0cm (OR=8.408, P<0.01), infiltration of the submucosal layer (OR=5.926, P=0.009) and undifferentiated lesion (OR=4.880, P=0.020) were the independent risk factors. Conclusion Lymph node metastasis in early gastric carcinoma is significantly cantingent on the depth of infiltration, tumor size and histological type.
3.Prognostic value of PR in Luminal B HER2 (-) lymph-node-negative breast cancer
Ying LIU ; Yan MAO ; Weihong CAO ; Haibo WANG ; Yunjiao WANG
Chinese Journal of Endocrine Surgery 2017;11(2):101-106
Objective To assess the prognostic value of progesterone receptor (PR) in Luminal B HER2(-) lymph-node-negative breast cancer.Methods The clinical data of 196 Luminal B HER2 (-) lymph-node-negative breast cancer patients were collected in this study.The correlation between PR and clinicopathological factors and its influence on prognosis was analyzed.Results Among 196 patients with Luminal B HER2 (-) lymph-node-negative breast cancer,14.8%(29/196)were PR-negative and 85.2%(167/196)were PR-positive (HR=3.25,95.0% CI:0.73-1.45,P=0.123).PR negativity indicated postmenopausal status (P=0.029) and high tumor grade (P=0.001).Mter a median follow-up of 60 months,9.7%(19/196) of the patients had relapses and 4.1%(8/196) died of breast cancer.The 5-year disease-free survival(DFS) was 75.9% in PR-negative group and 92.8% in PR-positive group (Log-rank P=0.001).The 5-year overall survival (OS) was 89.7% in PR-negative group and 97.0% in PR-positive group (Log-rank P=0.023).In multivariate analysis,PR negativity was significantly associated with a poor 5-year DFS (HR=2.85,95.0% CI:1.05-7.72,P=0.039)but not with 5-year OS (HR=1.78,95.0% CI:0.34-9.35,P=0.495).Conclusion In this study,PR is a prognostic factor for relapse in Luminal B HER (-) lymph-node-negative breast cancer.
4.The surgical management of advanced gastric carcinoma with portal hypertension
Yanbing ZHOU ; Shikuan LI ; Jianli ZHANG ; Haibo WANG ; Weizheng MAO ; Lianan DING ; Guanjun YU
Chinese Journal of General Surgery 2001;0(07):-
Objective To review the experience on the surgical management for advanced gastric carcinoma with portal hypertension. Methods In this study, 14 advanced gastric carcinoma with portal hypertension patients were analyzed retrospectively, liver cirrhosis was found in 13 cases. In 10 esophageal variceal patients, 5 had upper gastrointestinal bleeding history. All of those cases were associated with different degree of hypersplenism. The tumours situated at the upper third of the stomach in 2 patients, middle and upper third in 2 and lower third in 10. Five patients underwent curative distal subtotal gastrectomy and splenectomy, 2 cases did radical distal subtotal gatrectomy and pericardial devascularizaion, 2 curative distal subtotal gastrectomy combined with splenic artery ligation,2 did total gastrectomy and pericardial devascularizaion,2 cases did radical proximal gastrectomy and pericardial devascularization and 1 patient did distal subtotal gastrectomy only. Results Three died from extensive wound bleeding, jejunal fistula and liver failure respectively. 3 patients were complicated by left subdiaphragmatic abscess, hepatic dysfunction and massive ascites individually. The morbidity and mortality rate were 42.86% and 21.43% respectively. Conclusion The surgical procedures for patients of advanced gastric carcinoma with portal hypertension caused a considerably high postoperative mortality and morbidity rate.
5.Progress and challenge of neoadjuvant therapy for breast cancer
Wenjing LIU ; Yan MAO ; Haibo WANG
Journal of Clinical Surgery 2018;26(1):73-76
With the development of medical technology,the treatment of breast cancer has en-tered into a comprehensive treatment age which combines chemotherapy,radiotherapy,endocrine therapy and molecular targeting therapy from the time of local treatment. Neoadjuvant therapy has been widely ap-plied in clinic due to many advantages,such as lowering the primary breast tumor and axillary lymph node,improving breast conserving rate and predicting drug sensitivity. With the emergence of molecular typing of breast cancer,neoadjuvant therapy has changed from primary neoadjuvant chemotherapy to the comprehensive treatment with neoadjuvant chemotherapy,neoadjuvant endocrine therapy and neoadjuvant targeted therapy. Here is a review of the progress of neoadjuvant therapy,evaluation of curative effect,se-lection of operation mode and challenges of neoadjuvant therapy from different molecular typing of breast cancer.
6.Effects of the combination therapy of probucol with atorvastatin on serum hs-CRP,ox-LDL and MMP-9 levels and carotid plaque in patients with acute cerebral infarction
Yunhua YUE ; Xudong BAI ; Xiaoning ZHANG ; Jieping MAO ; Namu DILA ; Reyi MIHE ; Xiaoying YANG ; Haibo ZENG
Chinese Journal of Nervous and Mental Diseases 2014;(11):641-645
Objective To explore the influence of the combination therapy of probucol with atorvastatin on levels of serum high sensitivity C-reactive protein (hs-CRP), oxidized low-density lipoproteins (ox-LDL), and marix metallopro? teinase-9 (MMP-9) and resolution of carotid plaque in patients with acute cerebral infarction (ACI). Methods One hun? dred-six patients with acute cerebral infarction who had carotid artery color Doppler ultrasound-confirmed atherosclerot? ic plaques , were included in the present study. The patients were randomly divided into two groups: conventional treat? ment group ( 40 cases) which received atorvastatin (20mg/d) and co-treatment group (40 cases) which received Atorvas? tatin (20mg/d) and Probucol (500mg/d). Levels of hs-CRP, ox-LDL and MMP-9 were detected in all patients before treat? ment and 1, 6 and 12 months after drug therapy. The Intima-media thickness, area and numbers of carotid plaques were evaluated by using Doppler ultrasonography during a 12 months follow-up period. Results ① Serum hs-CRP and MMP-9 levels were significantly decreased at 1, 6 and 12 months after treatment, (conventional treatment group:t =14.662, 23.586, 28.179 and co-treatment group:t =47.023, 50.239, 50.774,P <0.01). The ox-LDL levels was obviously de? creased in the combined treatment group (t =4.592, 5.011, 5.892,P <0.01) but not in conventional treatment group (P > 0.05) at 1, 6 and 12 months after treatment. Serum hs-CRP, ox-LDL and MMP-9 levels were significantly lower in com? bined treatment group than in the conventional treatment group at all time points after treatment (t =7.655, 5.271, 2.492, t =4.927, 3.772, 4.673 andt =16.862, 4.251, 2.045.P <0.01 orP <0.05). ②There were not statistically differences in the IMT, plaque area and plaque numbers between these two groups before treatment (P >0.05). The IMT, plaque area and plaque numbers were significantly smaller in combined treatment group than in conventional treatment group (t =6.117, 3.290, 2.158,P <0.05). Conclusions The combination therapy of probucol with atorvastatin can greatly reduce levels of serunl hs-CRP,ox-LDL and MMP-9, indicating that the combination therapy has a strong anti-oxidant function, thereby reversing and stabilizing the atherosclerosis plaque.
7.Study on the changes of gonadotropin releasing hormone agonist in pinopodes
Weiqin ZHOU ; Yali JIANG ; Haibo TANG ; Hongyang GAO ; Yanyan ZHUANG ; Fei XIA ; Caiping MAO ; Chunrong ZHU
Chinese Journal of Obstetrics and Gynecology 2017;52(8):539-544
Objective To study the changes of gonadotropin releasing hormone agonist (GnRH-a) in pinopodes during luteal phase and to explore the possible mechanism of GnRH-a in luteal phase support of assisted reproductive technology (ART).Methods Totally 40 primary infertility women who were treated with ART due to male factors were enrolled,according to the order of the group they were randomly divided into experimental group and control group.On the 7th day after ovulation,the experimental group received a subcutaneous injection of 0.1 mg of GnRH-a,while the control group received a subcutaneous injection of placebo only (0.9% salinc 2 ml),3 days later they came to the clinic again.Serum estradiol and progesterone levels were measured before and after treatment in each group.Pinopodes were collected for electron microscopic examination.Levels of ER and PR were detected by western blot.Results (1) There was no significant difference between the experimental group and the control group in the estrogen level before and after the treatment (all P>0.05).The level of progesterone in the experimental group after treatment [(66.8± 14.9) nmol/L] was significantly higher than that before treatment(P<0.05);also significantly higher than the same period of the control group (P<0.05).(2) There was no significant difference in the expression of ER protein in the experimental group before and after treatment (P>0.05).The expression of PR in the experimental group after treatment was significantly lower than that before treatment (P<0.05);also lower than the same period of the control group (P<0.05).(3) Expression amount of pinopodes in the experimental group after treatment was significantly higher than that before treatment [65% (13/20) versus 25% (5/20),P< 0.05],and the development trend was more mature [the percentage of maturation:75% (15/20) versus 35% (7/ 20),P<0.05].Expression amount of pinopodes after treatment and the percentage of maturation in the experimental group were significantly higher than those in the same period of control group (P<0.05).Conclusion GnRH-a in luteal phase support may play a role through the corpus luteum,which may promote the secretion of progesterone,downregulation of PR expression,promote the growth of pinopodes,and improve the endometrial receptivity.
8.Expression of HBcAg in hepatocytes and its association with the efficacy of antiviral therapy
Xihua FU ; Xuan HUANG ; Guojun SHEN ; Haibo LOU ; Yuqiao MAO
Journal of Clinical Hepatology 2021;37(6):1299-1303
ObjectiveTo investigate the effect of the expression of HBcAg in hepatocytes on the serum level of HBcAb and seroconversion of HBeAg after antiviral therapy with nucleos(t)ide analogues (NUCs). MethodsSerum samples and liver tissue paraffin sections were collected from 101 chronic hepatitis B (CHB) patients who received antiviral therapy with NUCs in Nanfang Hospital and Panyu Central Hospital from January 2015 to June 2018. ELISA was used to measure the serum level of HBcAb, and immunohistochemistry was used to measure the expression of HBcAg in the liver. The GEO database (GSE96851) was analyzed to obtain differentially expressed genes in the liver of patients with HBcAg-positive hepatitis. The two-independent-samples t test was used for comparison of continuous data between two groups; the multiple-independent-samples nonparametric Kruskal-Wallis H test was used for comparison of continuous data between multiple groups, and Dunnett method was used for further comparisons; the chi-square test was used for comparison of categorical data between groups. ResultsThe expression pattern of HBcAg in hepatocytes was classified as absent expression, nuclear expression, cytoplasmic expression, and nuclear/cytoplasmic expression, and according to expression level, HBcAg expression was classified as grades Ⅰ, Ⅱ, Ⅲ, and Ⅳ expression. HBeAg seroconversion rates after 96 weeks of antiviral therapy were 5.88%, 16.67%, 22.73%, and 24.24%, respectively, in the patients with absent expression, nuclear expression, cytoplasmic expression, and nuclear/cytoplasmic expression (χ2=4753, P=0.037), and HBeAg seroconversion rates after 96 weeks of antiviral therapy were 5.88%, 13.04%, 27.59%, and 26.67%, respectively, in the patients with grade Ⅰ, Ⅱ, Ⅲ, and Ⅳ expression (χ2=6.580, P=0.016). There were significant differences in the serum levels of HBcAb-IgM and total HBcAb between the patients with absent expression, nuclear expression, cytoplasmic expression, and nuclear/cytoplasmic expression of HBcAg (HBcAb-IgM: H=9.760, P=0.021; total HBcAb: H=21.46, P<0.001), and there were also significant differences in the serum levels of HBcAb-IgM and total HBcAb between the patients with grade Ⅰ, Ⅱ, Ⅲ, and IV expression of HBcAg (HBcAb-IgM: H=18.80, P<0.001; total HBcAb: H=26.03, P<0.001). The analysis of differentially expressed genes in the liver showed that the expression of antibody-related genes was upregulated in the liver of patients with HBcAg-positive acute liver failure. ConclusionThe expression pattern and level of HBcAg in the cytoplasm of hepatocytes are associated with serum HBcAb, and the measurement of HBcAg may help to predict the efficacy of antiviral therapy with NUCs.
9.Surveillance for avian influenza virus in environments in Liaoning Province
Lulu WANG ; Haibo SUN ; Baihong SUN ; Shuang LIU ; Yichun SONG ; Lingling MAO ; Yingwei SUN ; Wenqing YAO
Journal of Preventive Medicine 2019;31(3):221-224
Objective :
To learn the epidemic distribution of avian influenza virus in external environments in Liaoning Province,and to provide evidence for the prevention and control of avian influenza.
Methods :
The environmental samples were collected monthly during 2016 and 2017(including samples from emergency monitoring in June to August,2016 and March to May,2017)from live poultry markets,live poultry wholesale markets,large-scale poultry farms(households),free-range poultry famers and poultry processing factories in Liaoning Province. Real-time polymerase chain reaction assay was used to detect nucleic acid of Influenza A as well as H5,H7 and H9 subtypes in the environmental samples. The distribution of avian influenza virus in external environments in Liaoning Province was analyzed.
Results :
A total of 4 037 environmental samples were collected and detected from 2016 to 2017,there were 177 copies of type A avian influenza virus and the positive rate of avian influenza A virus was 4.38%. The positive rate in 2017 was 6.26%, which was higher than 2.40% in 2016(P<0.05). H9 subtype had the highest positive rate of 3.07%;H7 subtype was first detected in 2017. The positive rates of avian influenza virus from the first to fourth quarters of a year were 8.54%,4.88%,2.17% and 1.45%,respectively. The positive rates of avian influenza virus in live poultry markets were 8.08%,the highest among different sites,and the subtypes were mainly H9. The positive rates of avian influenza virus in samples of poultry cage and poultry washing sewage were 23.47% and 15.96%. H5 and H9 subtypes were detected in all types of samples,and H7 subtypes or mixed types were detected in samples of feces,poultry cage,poultry drinking water and chopping board.
Conclusion
The subtypes of avian influenza virus in the environments of Liaoning Province were mostly H9 and H5,and the H7 was first detected in 2017. Live poultry markets should be the key monitoring sites,especially in winter and spring.
10. The value of non-invasive prenatal testing for the identification of fetal chromosome aneuploidies
Ying ZHOU ; Zhenyu WANG ; Qianqian MAO ; Danhua SHI ; Lichao ZHANG ; Lingling XU ; Haibo LI
Chinese Journal of Medical Genetics 2019;36(11):1094-1096
Objective:
To assess the value of non-invasive prenatal testing (NIPT) for the identification of fetal chromosomal aneuploidies.
Methods:
For 9470 pregnant women with a moderate-to-high risk by conventional serological screening or advanced maternal age, peripheral venous blood samples were collected and, following extraction of free fetal DNA, subjected to large-scale parallel sequencing on a Illumina Hiseq2000 platform. Those with a high risk by NIPT were validated by invasive prenatal diagnosis.
Results:
Out of the 9470 samples, 194 cases (2.0%) were positive by NIPT testing. These included 50 trisomy 21, 11 trisomy 18, 17 trisomy 13, 44 other autosomal aneuploidies, 55 sex chromosomal aneuploidies, and 17 chromosomal copy number variations. As validated by amniotic fluid or umbilical blood chromosomal karyotyping analysis, NIPT has a false positive rate of 2.0%, 18.2%, 41.2%, 97.7%, 81.8%, 94.1%, respectively. The test has a sensitivity of 100% and a specificity of 98.79%.
Conclusion
For common chromosomal aneuploidies such as trisomy 21 and trisomy 18, NIPT has a good sensitivity and specificity, therefore has good value for clinical application.